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Abstract
Novel psychoactive substances (NPS) continue to represent a threat to public health and safety. The number of new drugs in the latest emergent
synthetic opioid class—the 2-benzylbenzimidazole analogs—also called the nitazenes—has begun to dominate the current new synthetic opioid
(NSO) subclass of NPS. We describe a liquid chromatography–tandem quadrupole mass spectrometry method for the quantification of nine
analogs and/or metabolites of drugs in this series: isotonitazene, metonitazene, protonitazene, etonitazene, clonitazene, flunitazene, N-desethyl
isotonitazene, 5-amino isotonitazene and 4′ -hydroxy nitazene in human whole blood, urine, and tissue. Samples were prepared for analysis
using a basic liquid–liquid extraction. Chromatographic separation was achieved using a C-18 analytical column. Multiple reaction monitoring
mode was used for detection. The calibration range for the analytes was 0.5–50 ng/mL (except for 5-amino isotonitazene, which was 1.0–
50 ng/mL). The limit of detection was 0.1 ng/mL, and the limit of quantitation was 0.5 ng/mL. The method had no carryover or interferences.
Ionization enhancement was observed but did not affect quantitation. All analytes passed the method validation assessment. Authentic human
samples suspected of containing NSOs were obtained from a medical examiner and coroner offices, as well as partnering forensic toxicology
laboratories. Isotonitazene was confirmed in 92 blood samples, and its metabolites were confirmed across various matrices. Metonitazene
(n = 35), flunitazene (n = 5), protonitazene (n = 3), etodesnitazene (n = 2) and butonitazene (n = 1) were also detected in cases. These newly
emerging 2-benzylbenzimidazole analogs were commonly found in combination with NPS benzodiazepines and opioids (e.g., flualprazolam,
fentanyl). Nitazene analogs are potent esoteric drugs that may not be identified during routine toxicological screening, and specialized assays
based on sensitive instrumentation are needed to accurately characterize these NSOs.

Introduction
Since the onset of the opioid epidemic, new synthetic opioids
(NSOs) have been reported as the largest contributors to drug
overdose deaths in the USA (1, 2). Starting in 2017, NSOs
outside of the fentanyl class began to proliferate, including
drugs that retain opioid agonist activity but vary in structure
and potency. The most recent NSO subclass to emerge and
proliferate is the 2-benzylbenzimidazoles or the ‘nitazenes’
(Figure 1). Several analogs in this subclass have since been discussed in online drug use forums, offered for sale online and
detected in drug materials. This subclass of analgesic drugs are
structurally distinct from fentanyl, fentanyl analogs and other
non-fentanyl analogs, such as U-47700, that were popular
between 2016 and 2020 (3).
Isotonitazene marked the beginning of the current rise of
nitazene analogs on the recreational drug market (4, 5). Isotonitazene is a structural analog of etonitazene, a potential
therapeutic agent first synthesized in 1957 as an analgesic;

however, etonitazene was never clinically approved for use
in humans (6, 7). When first studied, etonitazene was the
most potent drug of the 2-benzylbenzimidazole subclass with
potency estimated at 100–1,000 times that of morphine in
an animal model. From the same study, isotonitazene was
reported to be the second most potent drug in the series, followed by protonitazene, metonitazene and clonitazene. Since
this early work, additional nitazene analogs have been synthesized and studied, with potencies both greater than and less
than etonitazene (8, 9).
Like other synthetic opioids, nitazene analogs bind to and
activate µ-opioid receptors (MOR), yet little pharmacological information specific to these drugs is available regarding
pharmacodynamics and pharmacokinetics. In vitro evaluation of isotonitazene by Blanckaert et al. demonstrated that
isotonitazene is a strong opioid based on its high potency
and efficacy (4). The half-maximal effective concentration
(EC50 ) of isotonitazene was reported as 11.1 nM compared to

© The Author(s) 2021. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License
(https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium,
provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

Downloaded from https://academic.oup.com/jat/article/46/3/221/6430787 by oup user on 19 April 2022

1

222

Walton et al.

14.4 nM for fentanyl (8). Isotonitazene has a larger maximum
response than fentanyl and hydromorphone, as the efficacy
(Emax ) of isotonitazene was determined to be 180% the Emax
of hydromorphone, a value higher than the efficacy of fentanyl
(163%) (4). In addition to isotonitazene, N-desethyl isotonitazene (EC50 : 0.614 nM) and etonitazene (0.661 nM) also
demonstrated high potency, closely followed by protonitazene
(3.95 nM) and metonitazene (8.14 nM) (8). The potencies of
other members of this series studied by Vandeputte et al.
were lower than that of isotonitazene, including etodesnitazene (54.9 nM), clonitazene (140 nM), 4′ -hydroxy nitazene
(176 nM), flunitazene (377 nM), and 5-amino isotonitazene
(383 nM) (8).
Metabolism data for nitazene analogs are also limited;
however, an early study involving isotonitazene provided
insight into the likely metabolic pathways for newer members of the series. Four main metabolites of isotonitazene were
reported by Krotulski et al. by examining in vivo metabolism
following the ingestion of isotonitazene based on the presence
of the parent drug (Figure 1) (10). Isotonitazene was metabolized through N-dealkylation and O-dealkylation to produce
two primary urinary metabolites, N-desethyl isotonitazene
and N-desethyl O-desalkyl isotonitazene (10). Of interest,

N-desethyl isotonitazene was determined to exhibit higher in
vitro potency than etonitazene and was identified in fatalities
in which isotonitazene was present (8). A third metabolite,
5-amino isotonitazene, was produced by reduction of the
nitro group. The fourth metabolite O-desalkyl isotonitazene,
more commonly referred to as 4′ -hydroxy nitazene, was
produced by O-dealkylation. 4′ -Hydroxy nitazene is a universal metabolite of nitazene analogs containing the 5-nitro
group, N,N-diethylamine and an associated phenyl ether.
This common metabolite may help simplify analytical toxicology screening methods; however, the identification of this
metabolite in the absence of a parent drug could be indicative
of the ingestion of any member of the series with the above
common structural features. The metabolism of metonitazene
is similar to that of isotonitazene (8).
In the USA, isotonitazene was first reported in August
2019 but the drug was on the illicit drug market at least
as early as April 2019 (9). By October 2020, isotonitazene
was identified in more than 200 individual postmortem
(PM) death investigation cases in the USA (11). NMS Labs
(Horsham PA, USA) was receiving approximately 30–40 isotonitazene positive cases per month at the peak of its popularity (accounting for approximately 0.5% of all routine
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Figure 1. Structures of nitazene analogs included in analysis, as well as the metabolites of isotonitazene (box). Structures consist of the benzimidazole
core, nitro group, alkoxy benzyl group and ethylamine component.

NSO Nitazene Analogs by LC–QQQ-MS

Methods
Materials
Standard reference materials were purchased from Cayman
Chemical (Ann Arbor, MI) as powders and prepared at a concentration of 1 mg/mL in methanol, including isotonitazene,
protonitazene, metonitazene, etonitazene, clonitazene, flunitazene, N-desethyl isotonitazene, 5-amino isotonitazene,
4′ -hydroxy nitazene, butonitazene, etodesnitazene and

isotonitazene-d7 . Drug-free human blood was purchased
from BioIVT (Westbury, NY). Sodium borate decahydrate
was purchased from Sigma-Aldrich (St. Louis, MO). Ethyl
acetate, N-butyl chloride and liquid chromatography–mass
spectrometry (LC–MS)-grade water and methanol were purchased from Honeywell Chemicals (Charlotte, NC). Formic
acid was purchased from ThermoFisher Scientific (Waltham,
MA).

Sample quantitation
For quantitative analysis, two spiking solutions containing
nine initial drugs (isotonitazene, protonitazene, metonitazene,
etonitazene, clonitazene, flunitazene, N-desethyl isotonitazene, 5-amino isotonitazene and 4′ -hydroxy nitazene) were
prepared from the stock (1,000 ng/µL) by serial dilution in
methanol at final concentrations 1.0 and 0.1 ng/µL. An internal standard (ISTD) spiking solution of isotonitazene-d7 was
prepared at 0.1 ng/µL. The calibration range was evaluated
from 0.5 to 50 ng/mL in blood. Low, mid and high control concentrations were 1.6, 8 and 40 ng/mL, respectively, in
blood. Spiking solutions for butonitazene and etodesnitazene
were prepared individually.

Sample preparation
A basic liquid–liquid extraction was used (10). Blood (0.5 mL)
was aliquoted and spiked with the appropriate spiking solution. Internal standard (50 µL) was added to each sample at a
final concentration of 10 ng/mL. Borax buffer (1 mL, 10 mM,
pH 10.4) was added to each sample, followed by 3 mL of
extraction solvent (70:30 N-butyl chloride, ethyl acetate). The
samples were rotated for 15 min and centrifuged for 10 min at
4,600 rpm. The organic layer was transferred, and the samples
were dried under nitrogen at 35◦ C for approximately 30 min.
The samples were reconstituted in 200 µL of initial chromatographic conditions and transferred to autosampler vials.
Analysis was performed using a Waters Xevo TQ-S Micro
LC–tandem quadrupole mass spectrometer (LC–QQQ-MS)
(Milford, MA). Data were processed using Waters MassLynx™ Software (Milford, MA).

Instrument method development
Each drug was directly infused individually into the mass
spectrometer to determine optimal cone voltage and collision energy (Table I). Selected product ions are shown in
the order of abundance. Dwell time (ms) was calculated by
the software based on the number of precursor–product ion
transitions. The two to three most abundant fragment ions
were used to create a multiple reaction monitoring method.
Chromatographic separation was achieved using an Agilent
InfinityLab Poroshell C-18 120 (2.7 µm, 3.0 × 100 mm) analytical column. Mobile phase A (MPA) was 0.1% formic acid
in water and mobile phase B (MPB) was 0.1% formic acid in
methanol. The method used a linear reverse phase chromatographic gradient (60A:40B initial hold for 1 min, 70A:30B at
2 min, 40A:60B at 5.5 min, 60A:40B at 6 min, hold for 1 min).
The flow rate was 0.4 mL/min. The injection volume was 5 µL.
The column temperature was 30◦ C.

Method validation
The described method was validated according to a standard
set forth by the AAFS Standards Board (23). Only the initial
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forensic toxicology casework screened via mass spectrometry per month) (11, 12). Isotonitazene was commonly found
with novel psychoactive substance (NPS) benzodiazepines,
such as flualprazolam and etizolam, a phenomenon that has
become common for NSOs, including more recent nitazene
analogs (11). In the USA, isotonitazene was reported in many
states across the East and Midwest, including Illinois, Indiana, Ohio and Wisconsin (13, 14). In June 2020, the US Drug
Enforcement Administration announced its intent to schedule
isotonitazene under Schedule I of the Controlled Substances
Act in an effort to curb increasing fatalities associated with
this NSO; the temporary rule went into effect in August 2020
(15). This action placed isotonitazene alongside analogs etonitazene and clonitazene, which had been placed in Schedule
I in 1961 (16). Federal scheduling of isotonitazene had an
immediate, widespread impact on the prevalence of this drug,
leading to a precipitous decline in its popularity, but clearing
the way for the emergence and proliferation of other analogs.
Isotonitazene has also been reported in Europe and Canada
(3, 5).
Since the initial emergence of isotonitazene, several
nitazene analogs have subsequently been identified in toxicology samples and/or drug materials linked to forensic
investigations. Metonitazene, another one of the original
analogs synthesized in 1957, was first reported in the USA
in July 2020 (17). Butonitazene was reported in Ohio alongside metonitazene in January 2021, flunitazene was reported
together with metonitazene and clonazolam in March 2021
and etodesnitazene (a nitazene analog without the nitro
group) was reported in Oregon in February 2021 (18–20).
N-Pyrrolidino etonitazene (or etonitazepyne) and protonitazene were reported in May 2021 in West Virginia and
Iowa, respectively (21, 22). While most of these analogs were
included in the early patent literature, the emergence of new
nitazene analogs not found in the patents (e.g., N-pyrrolidino
etonitazene) suggests that the increasing popularity of this
subclass is beginning to drive creative clandestine synthesis for
eventual proliferation on illicit drug markets. Forensic laboratories should be prepared for the continued emergence of new
nitazene analogs with varying levels of potency and structural
features.
In late 2019, the initial proliferation of isotonitazene led
our laboratory to believe that the emergence of new nitazene
analogs could become a high-level public health and safety
concern. The prospect of new and emerging nitazenes in
impairment cases and fatalities prompted the need for a
proactive approach to anticipate future developments in drug
design and pre-emptively create innovative analytical methods
encompassing both current and potential future analogs. This
forward-thinking approach is part of our broader strategy to
have methods available to rapidly detect, quantify and report
the appearance of new drugs to stakeholders in public health,
public safety and forensic circles.
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Table I. Mass Spectrometer Detection Parameters

Compound
4′ -Hydroxy

RT (min)
nitazene

1.79

Product ions (m/z)

Dwell (s)

Cone (V)

Collision (V)

369.2

100.0a

0.011

46

0.011

60

0.011

48

0.011

48

0.011

48

0.011

66

0.011

52

0.011

46

0.011

46

0.011

50

0.011

46

0.011

52

24
32
26
46
34
22
42
22
34
20
20
18
56
24
36
36
22
52
42
20
52
42
20
52
42
24
46
52
20
52
42
18
40
42

Flunitazene

4.74

371.2

5-Amino isotonitazene

1.21

381.2

Metonitazene

4.57

383.2

N-Desethyl isotonitazene

6.45

383.2

Clonitazene

5.98

387.1

Etonitazene

5.76

397.2

Protonitazene

6.69

411.2

Isotonitazene

6.34

411.2

Isotonitazene-d7

6.34

418.2

Butonitazeneb

7.63

425.2

Etodesnitazeneb

2.81

352.2

a
b

72.0
100.0a
109.0
72.0
100.0a
72.0
100.0a
121.0
72.0
72.0a
311.9
130.0
100.0a
124.9
72.0
100.0a
106.9
72.0
100.0a
106.9
72.0
100.0a
106.9
72.0
100.0a
72.0
107.9
100.0a
106.9
72.0
100.0a
106.9
72.0

Quantification ion.
Not included in the scope of full validation—evaluated using standard addition only.

nine analogs (isotonitazene, protonitazene, metonitazene,
etonitazene, clonitazene, flunitazene, N-desethyl isotonitazene, 5-amino-isotonitazene and 4′ -hydroxynitazene) were
included in this validation. Validation experiments included
calibration model, bias/accuracy, precision, interferences,
recovery, matrix effects (ion suppression/enhancement), dilution integrity, carryover, limit of detection (LOD), limit of
quantitation (LOQ), processed sample stability and matrix
matching. An additional assessment of standard addition was
added.
A calibration model of seven non-zero calibration points
was evaluated in individual runs over 5 days. R2 values and
calibrator back-calculations were used to assess the performance. Passing performance included an R2 value greater
than 0.98 and back-calculations less than ±20% deviation.
Bias and precision studies were assessed concurrently in individual runs over 5 days by running control samples (e.g., low,
mid and high) in triplicate. Bias was acceptable within ±20%
of target concentration. Precision was evaluated within-run
and between-run and was acceptable at a threshold of less
than 20% for each concentration and run.
Interference studies were performed by assessing four
factors: matrix, internal standard, analyte and commonly
encountered drugs. Matrix interferences were evaluated using
10 sources of blank blood. Analyte and internal standard

interferences were determined by monitoring each individually without the other. Commonly encountered drug interferences were evaluated against more than 250 traditional, therapeutic, abused and NPS drugs commonly detected in forensic
toxicology casework to determine whether any interfered with
the analytes of interest.
Recovery, matrix effects and process efficiency were evaluated by preparing three sets of samples: unextracted, prespiked and post-spiked (10 ng/mL). These sample sets help
determine the efficiency of the sample preparation procedure,
the effects that the matrix have on the analytes (if any), and
the recovery of each analyte. Matrix effects (also referred to
as ion suppression or enhancement) were acceptable if the
average signal deviation was less than ±20% when comparing post-spike and unextracted samples. If the value exceeded
what was deemed acceptable, the laboratory needs to determine that the suppression or enhancement does not affect any
critical validation parameters (e.g., LOD, LOQ) (23).
The LOD was determined by fortifying drug-free blood
with decreasing concentrations of the analytes and analyzing
these samples in individual runs over 3 days. A passing LOD
exhibits a signal-to-noise (S/N) ratio greater than three, but
also must pass all criteria set forth in the method for acceptable identification (e.g., retention time, ion ratio, peak shape,
etc.). A decision point LOQ was determined by analyzing the
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Precursor ion (m/z)

NSO Nitazene Analogs by LC–QQQ-MS

Authentic samples
Various biological samples (n = 171) were received from
individual cases (n = 114) for the analysis for the presence of nitazene analogs. PM (n = 47) and driving-underthe-influence-of-drugs (DUID) (n = 67) cases were submitted

between 2019 and 2021 and analyzed on a rolling basis as
cases were triaged for quantitation. Cases originated from
medical examiner and coroners’ offices as well as partnering forensic toxicology laboratories. PM cases included 31
peripheral blood samples, 15 central blood samples, 6 unspecified blood samples, 1 serum sample, 26 urine samples, 3 bile
samples, 3 liver samples, 2 brain samples and 16 vitreous fluid
samples. DUID cases included 67 antemortem blood samples.
Blood, serum, urine and vitreous samples were stored refrigerated (approx. 4◦ C) for their life cycle. Bile, liver and brain
samples were stored in the freezer (approx. −20◦ C) prior to
shipment for analysis where they were thawed, prepared and
stored refrigerated thereafter. The total sample storage time
ranged from less than 1 month to up to 1 year and varied
with respect to an individual case.
These authentic samples were generally suspected to contain isotonitazene, metonitazene and/or other new synthetic
opioids. The authentic samples were prepared via the validated workflow described above and analyzed via the Waters
Xevo TQ-S Micro LC–QQQ-MS. For matrices other than
blood and urine, quantitative analysis was performed using
standard addition. Cases involving nitazene analogs outside
the scope of the fully validated method (e.g., butonitazene,
etodesnitazene) were screened by liquid chromatography
quadrupole time-of-flight mass spectrometry (LC–QTOF-MS)
and subsequently quantitated using standard addition with
analysis by LC–QQQ-MS, after verification of the standard
addition process for each drug (24).

Results and Discussion
Method development and validation
Chromatographic separation (Figure 2) of the nitazene
analogs was observed within this 7-min method. Special attention was given to isotonitazene and protonitazene—two very
closely related positional isomers (Figure 1) that cannot be
distinguished based on mass spectral analysis alone.
Table II shows the quantitative parameters for each
nitazene analog assessed via full validation. The calibration
model for all drugs was linear with 1/x weighting and the origin excluded. The final calibration range was 0.5–50 ng/mL
for all analytes except for 5-amino isotonitazene, which
had an amended calibration range of 1.0–50 ng/mL due
to the method’s inability to accurately quantitate down to
0.5 ng/mL. All drugs passed the calibration model studies
with R2 values at or above 0.98. The LOQ for all drugs
was 0.5 ng/mL, with the exception of 5-amino isotonitazene,
which had an LOQ of 1.0 ng/mL. The LOD for all drugs was
0.1 ng/mL.
All nine nitazene analogs fell within the acceptable criteria for bias and precision at all three control concentrations
(Table III). Recovery was greater than 85% for all drugs.
Matrix effects were greater than 100%, indicating ionization
enhancement for all drugs; however, there was no impact
on assay performance (e.g., accuracy, precision, peak shape,
etc.). Process efficiency was greater than 100% for all drugs;
however, this is not a metric commonly assessed in forensic
toxicology validations and therefore does not associate acceptance criteria in the standard document—like matrix effects,
there was no impact on assay performance. Isotonitazene,
protonitazene, etonitazene, clonitazene, flunitazene and Ndesethyl isotonitazene all were stable in the autosampler for
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lowest calibrator in individual runs over 3 days. A passing
LOQ must pass all criteria set forth in the method for quantitation (e.g., accuracy, retention time, ion ratio, peak shape,
etc.) and exhibit a S/N ratio greater than 10.
Carryover was evaluated in individual runs over 5 days by
analyzing blank samples directly after the highest calibrator
(50 ng/mL). Blank samples must be free of signal (i.e., chromatographic peak) or absent signal that could affect the assay
performance. Dilution integrity was assessed in individual
runs over 5 days in triplicate by diluting the middle calibrator (10 ng/mL) with deionized water at 1:2 and 1:4. Diluted
samples must still pass all criteria for identification and quantitation, as well as criteria for bias (±20%) and precision
(20%) across runs.
Processed sample stability was evaluated over four nonconsecutive days by re-analyzing control samples from the
initial validation run and comparing the response over time.
The controls were stored in the autosampler until the next validation run was prepared. The analytes were considered stable
if they passed all quantitative criteria and/or did not change
significantly (±20%) in response.
A matrix matching study was performed by preparing control samples in quintuplicate in urine. These controls in urine
were compared against the blood calibration curve. The assay
was considered ‘matrix matched’ if the quantitative values
were within ±20% that of the target value.
Although not required, standard addition studies were
added as part of this validation to allow for the analysis of other matrices. Standard addition can help alleviate
issues arising from matrix effects and provides an avenue
for quantitation when typical full validation experiments
(as described above) are not performed. This process can be
especially useful for infrequently encountered alternate matrices, such as the liver and bile, when the blank authentic
matrix is not available for validation studies. Standard addition was performed by preparing two pools of blood at
different concentrations (5 and 10 ng/mL). These pools were
aliquoted (0.5 mL) in quadruplicate and up-spiked with a
known drug (sample 1: no drug, sample 2: 0.5 ng/mL, sample
3: 5 ng/mL and sample 4: 50 ng/mL). The peak area ratio from
each aliquot was plotted against the up-spiked concentration.
The R2 value was expected to be at least 0.98. The sample was expected to quantitate within 20% of the prepared
concentration.
A full drug stability assessment was included for these
nitazene analogs. A pool of blood was fortified with all analytes at a concentration of 10 ng/mL. This pool was aliquoted
(0.5 mL), and the individual aliquots were stored at varying
temperatures: freezer (−20◦ C), refrigerator (4◦ C) and room
temperature (∼20◦ C). Aliquots were extracted and analyzed
in triplicate at varying time points: 0 h, 24 h, 48 h, 7 days,
14 days, 28 days and 60 days. A fresh calibration curve and
controls were prepared for each individual analysis. Analytes were considered stable until there was a loss of >20%
concentration or the criteria needed for identification and
quantitation were not met.
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Table II. Quantitation Parameters and Calibration Results

Compound

Calibration
rangea (ng/mL)

Model

Weighting

LOQ (ng/mL)

LOD (ng/mL)

Correlation
(R2 )

y-Intercept

Isotonitazene
Protonitazene
Etonitazene
Metonitazene
Clonitazene
Flunitazene
N-Desethyl isotonitazene
5-Amino isotonitazene
4′ -Hydroxy nitazene

0.5–50
0.5–50
0.5–50
0.5–50
0.5–50
0.5–50
0.5–50
1.0–50
0.5–50

Linear
Linear
Linear
Linear
Linear
Linear
Linear
Linear
Linear

1/x
1/x
1/x
1/x
1/x
1/x
1/x
1/x
1/x

0.5
0.5
0.5
0.5
0.5
0.5
0.5
1.0
0.5

0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1

0.999
0.999
0.999
0.998
0.999
0.998
0.998
0.998
0.998

0.16
0.13
0.17
0.23
0.20
0.30
0.11
0.27
0.12

a

Calibrator values were 0.5, 1, 2, 5, 10, 20 and 50 ng/mL.

up to 216 h (9 days). 5-Amino isotonitazene was stable for up
to 192 h (8 days), and metonitazene and 4′ -hydroxy nitazene
were stable for less than 120 h (5 days).
No interferences and no carryover were observed for this
assay. All analytes passed dilution integrity studies except for
5-amino isotonitazene, which showed unacceptable bias and
variation for both the 1:2 and 1:4 dilutions. 5-Amino isotonitazene was also the only analyte that failed matrix matching
studies; all others met the criteria. As a result, it was determined that this method is only valid for 5-amino isotonitazene
if the matrix of the sample is blood and undiluted.
All nine analogs met the necessary criteria for the two standard addition experiments performed. All drugs exhibited
R2 values greater than 0.99. The percent deviation was less
than 10% from the target concentration for both the 5 and
10 ng/mL samples for all drugs.

Overall, our laboratory was able to develop an LC–QQQMS assay for the simultaneous quantitation of nine nitazene
analogs, including two isomers (protonitazene and isotonitazene) and parent drugs and metabolites. The assay passed
validation with exceptional performance. Ultimately, the
method was able to identify this drug subclass with significant
sensitivity in sub-ng/mL concentrations.

Stability assessment
A stability assessment was conducted over 60 days in blood at
three storage conditions: freezer (−20◦ C), refrigerator (4◦ C)
and room temperature (∼20◦ C). All nitazene analogs were
observed to be stable under refrigerated conditions except
for 5-amino isotonitazene (Figure 3). During the quantitation of stability samples, 5-amino isotonitazene failed criteria
needed for quantitation (i.e., accuracy of control values).
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Figure 2. Chromatographic separation achieved (at 50 ng/mL). From left to right: 5-amino isotonitazene (1.21 min), 4′ -hydroxy nitazene (1.79 min),
metonitazene (4.57 min), flunitazene (4.74 min), etonitazene (5.76 min), clonitazene (5.98 min), isotonitazene (6.34 min), N-desethyl isotonitazene
(6.45 min) and protonitazene (6.69 min).
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This was anecdotally attributed to the poor stability of
this metabolite; however, further research is warranted. 5Amino isotonitazene is included in Figure 3 for reference
only.
At room temperature, all nitazene analogs were stable for
up to 60 days except for isotonitazene (≥14 days), protonitazene (≥14 days), N-desethyl isotonitazene (≥7 days) and
4′ -hydroxy nitazene (≥14 days). Stability results for nitazene
analogs in the freezer were inconsistent, as most parent drugs
were observed to be unstable after 28 days—further assessment is warranted. The Supplementary File contains figures
for stability at room temperature (Figure S1) and frozen
(Figure S2). For reliable results, blood samples suspected to
contain a nitazene analog can generally be stored in the refrigerator (4◦ C) for at least 28 days before analysis based on the
data generated from this study.

Method additions and verification
Following validation, subsequent iterations of the method
were developed to included newly emergent nitazene analogs
butonitazene and etodesnitazene, which were assessed via
standard addition rather than traditional quantitation by
the calibration curve. Etodesnitazene was added to the initial method without the need for chromatographic changes
as it eluted (2.81 min) within the original run time. For
butonitazene, the chromatographic gradient was adjusted
due to this drug eluting after the full run time of the initial method. The final organic hold (40A:60B) in the gradient was lengthened from 0.5 to 1.5 min. This allowed
butonitazene to elute (7.63 min) properly for detection and
quantitation.
The standard addition verification process was acceptable
for both butonitazene and etodesnitazene. Both assays were
determined to be linear between 0.2 and 50 ng/mL. The LOD
values for both analytes were determined to be less than
0.1 ng/mL. No interferences from the matrix, analyte, internal
standard or commonly encountered drugs were discovered.
Simulated scenarios of standard addition were acceptable:
for butonitazene, the control prepared at 5 ng/mL resulted in
quantitation at 5.9 ng/mL (+18%) and the control prepared
at 10 ng/mL resulted in quantitation at 9.8 ng/mL (−2%) and
for etodesnitazene, the control prepared at 5 ng/mL resulted
in quantitation at 5.2 ng/mL (+4%) and the control prepared
at 10 ng/mL resulted in quantitation at 8.9 ng/mL (−11%).
Recovery for butonitazene was 88% and the recovery for
etodesnitazene was 80%.

Low
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Comprehensive confirmation results for PM and DUID
samples are shown in Table IV. Isotonitazene (n = 25),
N-desethyl isotonitazene (n = 13), metonitazene (n = 35),
protonitazene (n = 4), butonitazene (n = 3), etodesnitazene
(n = 1), flunitazene (n = 4) and 4′ -hydroxy nitazene (n = 10)
were confirmed quantitatively in PM samples analyzed using
this validated nitazene analog method. Only isotonitazene
(n = 50) and N-desethyl isotonitazene (n = 12) were confirmed in the DUID samples. Isotonitazene and metonitazene
were identified with the highest frequency. Isotonitazene
positive samples were collected between October 2019 and
January 2020, while metonitazene positive samples were collected between November 2020 and February 2021. This
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illustrates the quick turnover of these NSOs on recreational
drug markets. Brorphine, a non-nitazene NSO, was prevalent
in the months in between.
In total, isotonitazene was confirmed in 75 samples (44%),
including qualitative confirmations (<0.5 ng/mL) in 30 samples (18%): 13 PM and 17 DUID. Mean, median and range
concentrations are shown in Table IV. The mean and median
concentrations in blood were lowest for isotonitazene compared to the other analogs confirmed, likely owing to its
higher degree of potency. There was only one instance in a
DUID sample where isotonitazene was identified without the
presence of metabolites; all PM samples contained at least one
metabolite.
For DUID cases, N-desethyl isotonitazene was present in
96% (n = 64) of samples containing isotonitazene and 4′ hydroxy nitazene was present in 70% (n = 47). N-Desethyl
isotonitazene was found with isotonitazene in 24 PM samples
(96%), while 4′ -hydroxy nitazene was present with isotonitazene in 13 samples (52%). 5-Amino isotonitazene was
identified in PM samples with isotonitazene (n = 16, 64%) but
was not identified in DUID samples.
N-Desethyl isotonitazene was the primary metabolite
found with isotonitazene. N-Desethyl isotonitazene concentrations (Table IV) were slightly lower than isotonitazene;
N-desethyl isotonitazene is reported to have greater potency
than the parent drug, reinforcing the need to consider metabolites within the analytical scope (8). N-Desethyl isotonitazene
was found in urine and bile and at much higher concentrations
in bile than isotonitazene itself. The detection of N-desethyl
isotonitazene could be crucial to the interpretation of drug
concentrations following ingestion.

Metonitazene was found in combination with other
nitazene analogs. Metonitazene was discovered with flunitazene (n = 5), butonitazene (n = 3) and protonitazene (n = 2)
in blood, serum and urine. Metonitazene was confirmed in 35
(20%) PM samples, primarily blood (central, peripheral and
unspecified) and urine. The mean concentration of metonitazene in PM blood (Table IV) was observed to be higher than
that for isotonitazene. One serum sample contained 18 ng/mL
of metonitazene.
Butonitazene was confirmed in three (1.8%) PM samples:
unspecified blood (3.2 ng/mL), serum (2.4 ng/mL) and urine
(10 ng/mL). Flunitazene, one of the lesser potent nitazene
analogs, was confirmed in four (2.3%) PM samples: central
and peripheral blood (0.6–4.8 ng/mL) and urine (0.5 ng/mL).
In more recent months, protonitazene was confirmed in
four (2.3%) PM samples: central and peripheral blood (3.1–
25 ng/mL) and urine (1.0 ng/mL). As mentioned previously,
protonitazene was found along with metonitazene, and protonitazene was also discovered in combination with etodesnitazene (qualitative only). Etodesnitazene was quantified in a
separate central blood sample (30 ng/mL).
4′ -Hydroxy nitazene, the universal metabolite of the
nitazene analogs, was confirmed with isotonitazene (n = 6),
metonitazene (n = 2), protonitazene (n = 2) and butonitazene
(n = 1) in the PM samples. One sample contained both
metonitazene and butonitazene and in this instance the source
of the 4′ -hydroxy nitazene could not be attributed, although
it is likely that both parent drugs could each have produced
the metabolite. Mean and median bile concentrations were
elevated for this metabolite (mean: 64 ± 30 ng/mL, median:
52 ng/mL).
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Figure 3. Stability of nitazene analog parent drugs and isotonitazene metabolites in the refrigerator over 60 days. 5-Amino isotonitazene failed criteria for
calibration during quantitation, however, was included for reference.
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Table IV. Overall Results for Nitazene Analogs Confirmed (Including Both Quantitative and Qualitative)
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Other drugs commonly detected alongside isotonitazene
were flualprazolam, fentanyl and quinine (Figure 4). It is clear
from this case series that the nitazene analogs can be often
used with NPS benzodiazepines and other opioids, including
NPS opioids. These drugs are generally found at relatively low
concentrations (<10 ng/mL). N-Desethyl isotonitazene, however, was found at highly variable concentrations depending
on the matrix source (i.e., blood vs. bile).
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